A Single-Dose, Single Period, Phase II Pharmacokinetic Study To Examine Testagen TDS-Testosterone For Its Potential To Be Inadvertently Transferred By Skin Contact After Dosing In Healthy Adult Subjects
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2016
At a glance
- Drugs Testosterone (Primary)
- Indications Hypogonadism
- Focus Pharmacokinetics
- Acronyms TRANSFERENCE
- Sponsors Transdermal Delivery Solutions Corp
- 18 Oct 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2017.
- 18 Oct 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.
- 04 Apr 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.